23.5 C
New York
Thursday, July 3, 2025

Tag: life expectancy

newssourcecompanyFORcontentinformation1marketbusiness

Coventry Responds to Baseless Lawsuit by Abacus Global Management, Inc.

FORT WASHINGTON, Pa., July 02, 2025 (GLOBE NEWSWIRE) -- Coventry, the leader and creator of the secondary market for life insurance, today released the following statement:

AI Is Quietly Reinventing Healthcare–And Real Deployments Are Now Underway

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- Several experts are seeing that value of AI's total overhaul...

ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC

Virtual webinar on June 23, 2025 at 8:00 am ET 
Virtual webinar on June 23, 2025 at 8:00 am ET

Medical Biomimetics Market Share Set to Cross $55.36 Billion by 2030 with 7.6% CAGR- Exclusive Study by The Research Insights

CHICAGO, June 17, 2025 /PRNewswire/ -- The Global Medical Biomimetics Market is projected to be valued at USD 35.68 billion in 2024 and reach USD 55.36 billion by 2030, growing...

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical trial setting, enrolment and dosing of non-ambulatory patients will be immediately paused until additional risk mitigation measures (e.g. immune modulatory treatment) are implemented in the study protocol. Health authorities, investigators and physicians are being informed so that patient care can be quickly adjusted.

Abacus Global Management, Inc. (ABL) Shares Tumble Following Second Morpheus Report – Hagens Berman

SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- Investors in Abacus Global Management, Inc. (NASDAQ: ABL) experienced another substantial decline in share price today following the release of a second scathing report from Morpheus Research. Morpheus, a collective of financial analysts known for their focus on uncovering alleged fraud and corporate malfeasance, has now published two critical analyses of Abacus within a week, alleging the life settlements company has engaged in improper accounting.

Analyzing Gender Disparity in Retirement Savings—Strategic Insights for Financial Planning

**Retirement Planning: A Structured Approach for Long-Term Financial Security** All working Americans require robust retirement savings strategies, with a heightened focus necessary for women due...

Global News and The Local Win CJF Excellence Awards

TORONTO, June 12, 2025 /CNW/ - Global News is this year's recipient of the CJF Jackman Award for Excellence in Journalism in the large-media category, for...

Vascarta Receives FDA Orphan Drug Designation for Vasceptor® in the Treatment of Sickle Cell Disease

SUMMIT, N.J., June 12, 2025 /PRNewswire/ -- Vascarta Inc., a biopharmaceutical company committed to advancing innovative therapies for underserved patient populations, announced today that...

AS JUNE 19 WORLD SICKLE CELL AWARENESS DAY APPROACHES, COLLABORATIVE OF 47 COMMUNITY-BASED ORGANIZATIONS AND MEDICAL PROVIDERS PREPARE TO ‘SHINE THE LIGHT ON SICKLE...

COMMUNITY ACTION CAMPAIGN TO ILLUMINATE COMMUNITIES, RAISE AWARENESS, CALL FOR A UNIVERSAL CURE IN SUPPORT OF SICKLE CELL WARRIORS Historically African American Sororities And Fraternities...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abacus Global Management, Inc.- ABL

NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Abacus Global Management, Inc. (“Abacus” or the “Company”) (NASDAQ: ABL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsLife expectancy

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers